HC Wainwright Reiterates Buy Rating for Pharming Group (NASDAQ:PHAR)

Pharming Group (NASDAQ:PHAR)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $37.00 price target on the stock. HC Wainwright’s price objective points to a potential upside of 335.81% from the company’s previous close.

PHAR has been the subject of several other reports. Oppenheimer lowered their target price on shares of Pharming Group from $31.00 to $30.00 and set an “outperform” rating for the company in a research note on Monday, October 28th. Jefferies Financial Group started coverage on shares of Pharming Group in a research note on Monday, December 9th. They issued a “buy” rating and a $14.00 target price for the company.

Pharming Group Trading Down 3.5 %

Shares of Pharming Group stock opened at $8.49 on Tuesday. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.53 and a quick ratio of 2.76. Pharming Group has a 1 year low of $6.65 and a 1 year high of $13.20. The company has a market capitalization of $575.92 million, a P/E ratio of -32.65 and a beta of 0.05. The business has a 50 day moving average price of $8.28 and a 200 day moving average price of $8.13.

Institutional Investors Weigh In On Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC increased its holdings in shares of Pharming Group (NASDAQ:PHAR) by 75.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 41,110 shares of the company’s stock after acquiring an additional 17,675 shares during the quarter. Silverberg Bernstein Capital Management LLC owned approximately 0.06% of Pharming Group worth $339,000 at the end of the most recent quarter. 0.03% of the stock is currently owned by institutional investors.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.